Background: Alternatives to carbapenem are increasingly needed to decrease the usage of carbapenem. We evaluated the possibility of using non-carbapenem antibiotics against urinary tract infections (UTI) caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE). Methods: This retrospective study was performed at 2 university hospitals between October 2010 and December 2012. All diagnosed adult cases of ESBL-PE UTI were identified from the microbiological database. The subjects were divided into 3 groups based on the empirical antibiotic classes and susceptibility: carbapenem (C) group, susceptible non-carbapenem (SNC) group, and non-susceptible non-carbapenem (NSNC) group. Results: A total of 84 patients were eligible for analysis. For empirical therapy, 41, 23, and 20 patients were included in the NSNC, SNC, and C empirical groups, respectively. During the empirical therapy, 7 patients (17.1%) in the NSNC group, 18 patients (78.3%) in the SNC group, and 19 patients (78.3%) in the C group experienced clinical improvement. No significant difference was observed between the SNC and C empirical groups (P=0.192). Severe sepsis or shock was the predictor of empirical SNC treatment failure (P=0.048). There was a tendency to use carbapenem as a definite therapy in cases of NSNC. In contrast, empirical SNC was maintained as a definite therapy. Conclusion: SNC could be considered as an alternative to carbapenems for treating ESBL-PE UTI. This strategy might decrease the usage of carbapenem without clinical deterioration. However, it should be noted that SNC therapy may fail in the case of severe sepsis or shock.
Introduction
The incidence of infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) has steadily increased worldwide [1] . Since carbapenems are regarded as the first-line therapy for ESBL-PE infections, their use has also increased. However, the increasing prevalence of carbapenem-resistant Gram-negative bacteria has become an emerging problem [2] . Frequent exposure to carbapenems may result in the development of carbapenem resistance [3] . Therefore, there is a need for alternatives to carbapenems.
In recent years, several studies have evaluated the potential of non-carbapenem antibiotics as an alternative treatment for ESBL-PE infections [4] [5] [6] [7] [8] [9] [10] .
Previous studies have demonstrated that non-carbapenem alternatives could be used in limited situations. However, more definitive data are needed for their use for ESBL-PE infections. In addition, most previous studies have targeted bacteremia cases from various origins instead of organ-specific infections. One observational study reported that beta-lactam/beta-lactamase inhibitors were comparable to carbapenems for the treatment of ESBL Escherichia coli bacteremia [4] . In contrast, another study reported that the inhibitors appeared to be inferior to carbapenems for the treatment of ESBL bacteremia [11] . These inconclusive findings might be due to different proportions of bacteremia source. Therefore, caution is needed when generalizing these results to each site of infection.
In practice, urinary tract infections (UTI) are one of common organ infections caused by ESBL-PE [12] . Although a few observational studies have evaluated alternatives to carbapenems for the treatment of ESBL-PE UTI, most studies have focused on lower uncomplicated UTI [13, 14] . The purpose of this study was to evaluate the possibility of using non-carbapenem antibiotics for treatment of UTI caused by ESBL-PE. 
Materials and Methods

Results
Process for selecting eligible patients
During the study period, a total of 153 adult cases were culture-positive for ESBL-PE. Of these 153 cases, 130 patients had UTI. However, 29 patients presented with infectious foci other than UTI, 13 developed other infectious illnesses during treatment, and 4 were treated with combination antibiotic therapy. Therefore, a total of 84 patients were eligible for this study (Fig. 1 ). ities did not differ significantly among the 3 groups.
However, the total duration of antibiotic therapy was significantly longer in the NSNC group compared to that in the SNC and C groups (P=0.005). 
Risk factors
Discussion
There is limited clinical evidence regarding the use of non-carbapenem antibiotics for treatment of 
